Company intelligence / Profile preview

Dipexium Pharmaceuticals, Inc.

New York, New York, United Statessec.gov ↗

Ownership: Public · DPRX
Development stage: Phase 3

Overview

Dipexium's lead product Locilex (pexiganan cream 0.8%) failed to meet primary clinical endpoints in two Phase III studies in patients with mild diabetic foot ulcer infections. There was also evidence of a higher incidence of osteomyelitis and cellulitis in the Locilex treatment arms.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculePeptide
Industry: Biotech

Drug pipeline

1 asset

pexiganan

Phase 3

Indications: Mild diabetic foot infections, Moderate diabetic foot infections

Financials

Market cap: $9.5B
Total revenue: $5B
Enterprise value: $10.2B

Beyond the preview

Go deeper on Dipexium Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dipexium Pharmaceuticals, Inc..

Explore the full profile